A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits

Kanakatte Raviprakash; Thomas Luke; John Doukas; Janine Danko; Kevin Porter; Timothy Burgess; Tadeusz Kochel

doi:10.4161/hv.21806

A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits

Kanakatte Raviprakash^*, Thomas Luke, John Doukas, Janine Danko, Kevin Porter, Timothy Burgess, Tadeusz Kochel

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

A tetravalent DNA vaccine formulated with Vaxfectin adjuvant was shown to elicit high levels of neutralizing antibody against all four dengue virus serotypes (Porter et al., Vaccine 30:336, 2011), warranting further testing in humans. In preparation for a phase 1 clinical testing, the vaccine and the adjuvant were manufactured under current good manufacturing practice guidelines. The formulated vaccine and the adjuvant were tested for safety and/or immunogenicity in New Zealand white rabbits using a repeat dose toxicology study. The formulated vaccine and the adjuvant were found to be well tolerated by the animals. Animals injected with formulated vaccine produced strong neutralizing antibody response to all four dengue serotypes.

Original language	English
Pages (from-to)	1764-1768
Number of pages	5
Journal	Human Vaccines and Immunotherapeutics
Volume	8
Issue number	12
DOIs	https://doi.org/10.4161/hv.21806
State	Published - Dec 2012
Externally published	Yes

Keywords

DNA vaccine
Dengue
Immunogenicity
Rabbits
Vaxfectin

Access to Document

10.4161/hv.21806

Cite this

@article{f85cc012567344cab496cda2e0e1455a,

title = "A dengue DNA vaccine formulated with Vaxfectin{\textregistered} is well tolerated, elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits",

abstract = "A tetravalent DNA vaccine formulated with Vaxfectin adjuvant was shown to elicit high levels of neutralizing antibody against all four dengue virus serotypes (Porter et al., Vaccine 30:336, 2011), warranting further testing in humans. In preparation for a phase 1 clinical testing, the vaccine and the adjuvant were manufactured under current good manufacturing practice guidelines. The formulated vaccine and the adjuvant were tested for safety and/or immunogenicity in New Zealand white rabbits using a repeat dose toxicology study. The formulated vaccine and the adjuvant were found to be well tolerated by the animals. Animals injected with formulated vaccine produced strong neutralizing antibody response to all four dengue serotypes.",

keywords = "DNA vaccine, Dengue, Immunogenicity, Rabbits, Vaxfectin",

author = "Kanakatte Raviprakash and Thomas Luke and John Doukas and Janine Danko and Kevin Porter and Timothy Burgess and Tadeusz Kochel",

note = "Funding Information: This work was supported by funds from the Navy Bureau of Medicine and Surgery. Animal work was performed through a contract at the AAALAC accredited facilities of Bioreliance Corporation, in compliance with the Animal Welfare Act. The",

year = "2012",

month = dec,

doi = "10.4161/hv.21806",

language = "English",

volume = "8",

pages = "1764--1768",

journal = "Human Vaccines and Immunotherapeutics",

issn = "2164-5515",

number = "12",

}

A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits. / Raviprakash, Kanakatte; Luke, Thomas; Doukas, John et al.
In: Human Vaccines and Immunotherapeutics, Vol. 8, No. 12, 12.2012, p. 1764-1768.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits

AU - Raviprakash, Kanakatte

AU - Luke, Thomas

AU - Doukas, John

AU - Danko, Janine

AU - Porter, Kevin

AU - Burgess, Timothy

AU - Kochel, Tadeusz

N1 - Funding Information: This work was supported by funds from the Navy Bureau of Medicine and Surgery. Animal work was performed through a contract at the AAALAC accredited facilities of Bioreliance Corporation, in compliance with the Animal Welfare Act. The

PY - 2012/12

Y1 - 2012/12

N2 - A tetravalent DNA vaccine formulated with Vaxfectin adjuvant was shown to elicit high levels of neutralizing antibody against all four dengue virus serotypes (Porter et al., Vaccine 30:336, 2011), warranting further testing in humans. In preparation for a phase 1 clinical testing, the vaccine and the adjuvant were manufactured under current good manufacturing practice guidelines. The formulated vaccine and the adjuvant were tested for safety and/or immunogenicity in New Zealand white rabbits using a repeat dose toxicology study. The formulated vaccine and the adjuvant were found to be well tolerated by the animals. Animals injected with formulated vaccine produced strong neutralizing antibody response to all four dengue serotypes.

AB - A tetravalent DNA vaccine formulated with Vaxfectin adjuvant was shown to elicit high levels of neutralizing antibody against all four dengue virus serotypes (Porter et al., Vaccine 30:336, 2011), warranting further testing in humans. In preparation for a phase 1 clinical testing, the vaccine and the adjuvant were manufactured under current good manufacturing practice guidelines. The formulated vaccine and the adjuvant were tested for safety and/or immunogenicity in New Zealand white rabbits using a repeat dose toxicology study. The formulated vaccine and the adjuvant were found to be well tolerated by the animals. Animals injected with formulated vaccine produced strong neutralizing antibody response to all four dengue serotypes.

KW - DNA vaccine

KW - Dengue

KW - Immunogenicity

KW - Rabbits

KW - Vaxfectin

UR - http://www.scopus.com/inward/record.url?scp=84872223969&partnerID=8YFLogxK

U2 - 10.4161/hv.21806

DO - 10.4161/hv.21806

M3 - Article

C2 - 23032166

AN - SCOPUS:84872223969

SN - 2164-5515

VL - 8

SP - 1764

EP - 1768

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

IS - 12

ER -

A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits

Abstract

Keywords

Access to Document

Fingerprint

Cite this